While Chiang et al. showed that ACT of cblb-deficient CD8+ T cells into EG.7 tumor-bearing C57Bl/6 wt mice led to delayed tumor outgrowth or even eradication of established tumors (72), we found that sole ACT of polyclonal cblb-deficient CD8+ T cells in immunocompetent wildtype mice challenged with either EG.7 lymphoma or B16.ova melanoma, was not sufficient to significantly delay tumor growth (74). The gene discussed is CBLB; the disease is lymphoma.